WO2002076433A1 - Preparation dentaire - Google Patents

Preparation dentaire Download PDF

Info

Publication number
WO2002076433A1
WO2002076433A1 PCT/US2001/009754 US0109754W WO02076433A1 WO 2002076433 A1 WO2002076433 A1 WO 2002076433A1 US 0109754 W US0109754 W US 0109754W WO 02076433 A1 WO02076433 A1 WO 02076433A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
weight percent
amount
vitamin
active component
Prior art date
Application number
PCT/US2001/009754
Other languages
English (en)
Inventor
Gerald P. Curatola
David J. Shuch
Original Assignee
C.S. Bioscience, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C.S. Bioscience, Inc. filed Critical C.S. Bioscience, Inc.
Priority to JP2002574949A priority Critical patent/JP2004532831A/ja
Priority to US09/818,807 priority patent/US6503483B2/en
Priority to CA002441940A priority patent/CA2441940A1/fr
Priority to EP01274034A priority patent/EP1379223A4/fr
Priority to PCT/US2001/009754 priority patent/WO2002076433A1/fr
Publication of WO2002076433A1 publication Critical patent/WO2002076433A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A61K8/027—Fibers; Fibrils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • Oral hygiene products have been in use for centuries.
  • toothpaste typically consists of a mild abrasive dispersed in a gel or paste base, with detergents added to aid in cleaning, and fluoride added to reduce tooth decay.
  • Nutritional supplements have been in use for less than a century and typically are supplied in forms to be swallowed and digested for subsequent dispersal throughout the body. Over the past one hundred and fifty years certain medications have been formulated to be absorbed directly through the mucus membranes of the mouth. Building on the evidence of high absorbability of medications through the lining of the mouth, nutritional supplements are also now recognized to be able to be absorbed in this way. Further, homeopathic remedies have, since their inception, been routinely administered via this route.
  • an orally absorbable improved dental formulation includes a base to which an active component is added.
  • the active component includes one or more ingredients for physiologically and/or chemically reacting to the teeth or gums of a patient.
  • the active component comprises therein Vitamin C in an amount between about 10 and 25 weight percent, and coenzyme Q-10 (or ubiquinone) in an amount between 10 and 25 weight percent.
  • Vitamin C in an amount between about 10 and 25 weight percent
  • coenzyme Q-10 or ubiquinone
  • Nitamin E may be added to the active component of the inventive composition in an amount in the active component between about 10 and 25 weight percent.
  • Other ingredients that can be added to the active component include Nitamin A, the plant-based substance propolis, echinacea, and one or more homeopathic tissue salts.
  • the inventive dental composition consists of a toothpaste composition, which when used, boosts the user's immune response to gum disease and tooth decay in addition to cleaning the teeth and freshening the breath.
  • a toothpaste composition is preferred, the inventive formulation may be used in conjunction with a mouthwash or chewing gum. It may be also used in conjunction with dental treatment carriers such as prophylaxis paste and irrigation fluids.
  • the active component will include ubiquinone, but no Nitamin C, the ubiquinone will be present in an amount therein of between 10 and 25 weight percent.
  • Other ingredients, as discussed above, may be added to the active component.
  • Yet another object of the invention is to provide a dental composition which is edible and safe.
  • Yet a further object of the invention is to provide a nutritionally active dental composition.
  • Still another object of the invention is to provide a biologically absorbable dental composition.
  • the inventive dental formulation exclusive of the base to which it is added, includes, based on the overall weight of the active component, Nitamin C, and any precursor or derivative form thereof, in an amount between 0 and 25 weight percent and coenzyme Q-10 known as ubiquinone, in an amount also between about 10 and 25 weight percent.
  • the Nitamin C component is in the form of either sodium ascorbate and/or calcium ascorbate, both of which are pH neutral, slightly abrasive, yet easily absorbable forms of Nitamin C.
  • Nitamin C is used in the inventive dental formulation in order to promote healing of the mouth from gum disease, and to reduce plaque build-up on the teeth.
  • Coenzyme Q-10 is added to the inventive dental formulation for its known benefit in enhancing the health of the gums.
  • the active component of the dental formulation of the invention may also include Nitamin E in an amount between about 0 and 25 weight percent, also based on the weight of the active component.
  • the Nitamin E ingredient is added to the formulation in the form of d-alpha tocopherol, which may also contain in addition or instead d-beta, d-gamma and d-delta tocopherols.
  • This form of Vitamin E is may also be alpha tocopherols and/or Vitamin E esters.
  • the Vitamin E ingredient is added to the inventive formulation because of its recognized value in promoting the healing of gum tissue.
  • Vitamin A is added to the active component of the inventive formulation in an amount between about 10 and 25 weight percent bases on the total weight of the active component.
  • Vitamin A is preferably added in the form of water dispersed Vitamin A acetate, which is a dry fish oil free form of Vitamin A having the appearance of a beige powder.
  • Vitamin A is added to the inventive formulation for its recognized value in the promotion of gum tissue healing.
  • Propolis is added to the active component of the inventive formulation in an amount between about 5 and 15 weight percent.
  • Propolis is a plant-based substance used by bees in the construction of germ-free hives, and consists of a pale yellow powder.
  • Propolis is added to the inventive formulation since it is well known to facilitate the fight against bacterial infections, for its stimulation of phagocytosis, for its use as a salve on abraded, bruised or inflamed mucous membranes, and otherwise for its overall stimulation of the immune system.
  • Echinacea is added to the active component of the inventive formulation in an amount between about 3 and 10 weight percent.
  • Echinacea is an herbal extract of the Purple Cone Flower, and consists of a light brown liquid in a water/glycerin or water/10-20% alcohol vehicle.
  • Echinacea is added to the dental formulation for its recognized properties in boosting the immune system so that the body is resistant to bacteria and viruses. Echinacea is also effective in reducing inflammation and stimulating lymphatic tissue drainage.
  • Grape seed extracts and other anti-oxidants, methyl sulfonyl methane, pycnogenol, and refined or unrefined cocoa may also be added at levels of about 0% to 25% of the active component.
  • one or more homeopathic tissue salts may be included in the active component of the inventive formulation.
  • the sales are added to the active component in an amount between 5 and 25 weight percent.
  • the homeopathic tissue salt ingredient will consist of a complex of twelve homeopathic remedies, known collectively as the biochemic tissue salts. These consist of the following homeopathic tissue salts, each of which is in a potency in the range of between about 3X and 15X, and existing in an 80% water/20% alcohol medium.
  • Calc Fluor - used for its activity in reducing caries susceptibility and improving tissue elasticity.
  • Calc Phos - used for its activity in harmonizing bone and dental enamel metabolism.
  • Calc Sulph - used for its activity in purifying the blood and the tissues of the mouth, and for its role in improving the odor of the breath.
  • Ferr Phos - used for its action in mitigating inflammation and boosting the oxygen carrying capacity of the blood.
  • Kali Sulph - used for its activity in improving cellular metabolism and cell detoxification.
  • Mag Phos - used for its activity as a general tissue tonic.
  • Nat Sulph - used to improve gum tissue tone and to aid cells in purging intracellular toxins are used to improve gum tissue tone and to aid cells in purging intracellular toxins.
  • Silica - used in elimination toxins from tissues and improving tissue tone Silica - used in elimination toxins from tissues and improving tissue tone.
  • the homeopathic tissue formulation will be a four salt form comprising calc fluor, calc phos, calc sulph and silica.
  • the active component of the inventive formulation will include ubiquinone in an amount in the active component of from 10 - 25 weight percent.
  • the Vitamin C ingredient need not be added, but other active component ingredients can be added.
  • an optional component may also be added to and mixed with the active component base.
  • the optional component will consist of at least one of cranbeny extract, stevia, tangerine oil, and lemon oil.
  • Cranberry extract of the optional component would be present therein in an amount between about 20 and 50 weight percent.
  • Cranberry extract is a red liquid of the Viburnum Oplus beny and is used in the formulation for its ability to prevent the adherence of bacteria to various structures of the mouth, as well as for its use as a flavoring agent.
  • Cranbeny extract may be bought from most conventional health food stores in either the form of encapsulated powder of the extract or in a liquid form.
  • Stevia may be added to the optional component formulation in an amount therein between about 25 and 50 weight percent.
  • Stevia is an herbal extract of the Stevia Rebaudiana plant, and comprises a clear, slightly syrupy liquid. Stevia is used in the inventive formulation for its natural sweetness, while at the same time inhibiting the formation of plaque on teeth. It also serves the purpose of balancing the salty taste that is associated with the addition of sodium ascorbate (Vitamin C). Further, stevia reduces the craving for other plaque - and caries - producing sweets.
  • Tangerine oil may be part of the optional component in an amount between about 10 and 25 weight percent. Tangerine oil is the essential oil of the common fruit of the same name, and is merely added as a natural flavoring agent. Lemon oil may also be added in an amount between about 10 and 25 weight percent to the optional component, and like the tangerine oil ingredient, it is the essential oil of the common fruit of the same name. It is used in the composition as a natural flavoring agent.
  • the base component of inventive formulation will include water in an amount between about 5 and 20 weight percent and glycerine in an amount between about 10 and 40 weight percent.
  • the base preferably also includes abrasives such as calcium carbonate in an amount between about 20 and 40 weight percent and silica in an amount between about 20 and 40 weight percent.
  • the water component can either be filtered, distilled or deionized.
  • the glycerine component would preferably be vegetable glycerin, which is the sweet syrupy trihydroxy alcohol (C 3 H 8 0 3 ) derived from the manufacture of vegetable soap. It is added to the base both as a moisturizer and lubricant of the mouth, as well as to facilitate the cleansing of the teeth and the absorption of nutrients. It further functions as a liquid vehicle for forming the ingredients into an appropriate consistency.
  • the calcium component comprises an edible powder thereof.
  • the silica component comprises an edible powder made by milling the mineral quartz. It is used in the base of the inventive formulation as a mild abrasive and consistency modulator.
  • the inventive formulation as a toothpaste will include an active component amount between about 8 and 33 weight percent, and a base component in an amount between 65 and 90 weight percent. If one or more of the ingredients of the optional component is added, optional component will be present in the overall toothpaste formulation in an amount between about 0.5 and 5 weight percent.
  • Vitamin C 3.0% Vitamin E 3.7%
  • Lemon oil 0.13% Suitable formulations for the inventive toothpaste composition comprising just ubiquinone and other ingredients in the active component (other than Vitamin C) are as follows:
  • the inventive formulation may also be in the form of a dental prophylaxis paste.
  • the base component comprises water in an amount between about 5 and 25 weight percent and glycerin in an amount between about 10 and 50 weight percent. It may also include calcium carbonate in an amount between about 20 and 40 weight percent, and silica in an amount between about 20 and 40 weight percent.
  • the inventive formulation as a prophylaxis paste will comprise between about 10 and 50 weight percent of the active component, and 48 to 88 weight percent of the base component.
  • the optional component may be added in an amount between about 0.5 and 2 weight percent.
  • the most prefened prophylaxis paste composition in percent by weight is as follows:
  • prophylaxis paste composition comprising both Vitamin C and ubiquinone are as follows:
  • prophylaxis paste composition comprising just ubiquinone and other ingredients in the active component (other than Vitamin C) is as follows:
  • Vitamin A powder Vitamin A powder
  • Vitamin C powder Vitamin C powder
  • Vitamin E powder Vitamin E powder
  • Propolis and Co-enzyme Q-10 are first combined and milled together to yield a uniformly textured fine powder, which is the sum of the dry ingredients of the formulation.
  • glycerine water-, homeopathic tissue salts, Echinacea extract, Cranbeny extract, Stevia extract, Tangerine oil, and Lemon oil are combined and thoroughly mixed.
  • Essential oils such as lemon and tangerine oil may be use as solubilizers for the non-water soluble components of the active ingredient blend.
  • the dry ingredients of the formulation are then slowly added to the liquid ingredients while mixing, until a homogeneous slurry is produced.
  • inventive formulation herein include toothpaste, prophylaxis paste or gel, coated dental floss, coated interproximal dental brush, mouthwash, resorbable membrane for application to gums and oral mucosa, chewing gum, lozenge, topically applied gel - either tray or directly to the gums and teeth, for use by patient and/or dental professional, topically applied solution, coated toothbrush, candy-gum drops, chocolate pieces or bars, nougats, etc., probably sugar free and non-cariogenic and nutritional supplements either for topical application or for ingestion.
  • the required amount of the milled calcium carbonate and silica powder is added incrementally while stirring until all of this powder has been incorporated, resulting in a homogenous mass of a suitable, paste-like composition for use as, on the one hand, the p composition of the invention, or, on the other hand, the dental prophylaxis paste composition of the invention.
  • the inventive formulation will include a base and at least one of cranberry extract in an amount between about 0.1 and 5 weight percent and stevia (a specific herbal extract) in an amount between about 0.1 and 4 weight percent, the weight percents based on the overall weight of the formulation.
  • cranberry extract in an amount between about 0.1 and 5 weight percent
  • stevia a specific herbal extract
  • One or more active component ingredients, as discussed hereinabove, may be added to this alternative formulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Insects & Arthropods (AREA)
  • Animal Husbandry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Confectionery (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Brushes (AREA)

Abstract

L'invention concerne une préparation dentaire améliorée qui s'administre par voie orale. La préparation dentaire comprend une base à laquelle un constituant actif est ajouté. Le constituant actif comprend, sur la base de son poids total, 0 à 25 % en poids de vitamine C, et 0 à 25 % en poids de coenzyme Q-10 (ou ubiquinone).
PCT/US2001/009754 1997-06-12 2001-03-27 Preparation dentaire WO2002076433A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2002574949A JP2004532831A (ja) 2001-03-27 2001-03-27 歯科用調剤
US09/818,807 US6503483B2 (en) 1997-06-12 2001-03-27 Dental formulation
CA002441940A CA2441940A1 (fr) 2001-03-27 2001-03-27 Preparation dentaire
EP01274034A EP1379223A4 (fr) 2001-03-27 2001-03-27 Preparation dentaire
PCT/US2001/009754 WO2002076433A1 (fr) 2001-03-27 2001-03-27 Preparation dentaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/009754 WO2002076433A1 (fr) 2001-03-27 2001-03-27 Preparation dentaire

Publications (1)

Publication Number Publication Date
WO2002076433A1 true WO2002076433A1 (fr) 2002-10-03

Family

ID=21742443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009754 WO2002076433A1 (fr) 1997-06-12 2001-03-27 Preparation dentaire

Country Status (4)

Country Link
EP (1) EP1379223A4 (fr)
JP (1) JP2004532831A (fr)
CA (1) CA2441940A1 (fr)
WO (1) WO2002076433A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1607097A2 (fr) * 2003-08-21 2005-12-21 Neutrogena Corporation Compositions stabilisées renfermant des agents qui sont labiles en présence d'oxygène
WO2006109344A2 (fr) * 2005-04-13 2006-10-19 Gasparini, Gianluigi Composition pour le traitement de pathologie parodontale
WO2007061912A3 (fr) * 2005-11-23 2008-01-31 Coca Cola Co Composition d'edulcorant tres puissant avec un agent anti-inflammatoire et compositions sucrees avec celle-ci
US8173711B2 (en) 2007-01-31 2012-05-08 Kaneka Corporation Agent for relief or prevention of xerostomia
FR3012294A1 (fr) * 2013-10-25 2015-05-01 Ferco Dev Agents edulcorants a base de stevia.
EP2881105A1 (fr) * 2013-12-05 2015-06-10 PM-International AG Kit de produits de soin dentaire
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
JP5002623B2 (ja) * 2009-07-28 2012-08-15 ユーハ味覚糖株式会社 プロポリス含有キャンディ
CN102596154B (zh) 2009-10-29 2014-12-24 高露洁-棕榄公司 包含氟化亚锡加柠檬酸锌和低水平水的洁齿剂
KR101225308B1 (ko) * 2009-11-30 2013-01-25 김응완 항균 미백 칫솔모 및 그 제조방법
CA2799257A1 (fr) * 2010-06-24 2011-12-29 Colgate-Palmolive Company Composition de soins oraux comprenant une substance non dialysable extraite de canneberge
JP6523971B2 (ja) * 2014-02-17 2019-06-05 株式会社カネカ 還元型補酵素ｑ１０を含有する組成物
JP7368858B2 (ja) * 2018-09-21 2023-10-25 株式会社山田養蜂場本社 バイオフィルム形成抑制剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61286314A (ja) * 1985-06-11 1986-12-16 Shiseido Co Ltd 口腔用組成物
BE906034A (fr) * 1985-12-24 1987-04-16 Seuref Ag Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
WO1998056336A1 (fr) * 1997-06-12 1998-12-17 C.S. Bioscience Inc. Formulation dentaire

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63141921A (ja) * 1986-12-04 1988-06-14 Kao Corp 口腔用組成物
ES2283002T3 (es) * 1995-06-07 2007-10-16 The Howard Foundation Carotenoides farmaceuticamente activos.
JP3540904B2 (ja) * 1996-09-09 2004-07-07 大正製薬株式会社 歯磨き剤
JP3793625B2 (ja) * 1997-07-30 2006-07-05 花王株式会社 粉状歯磨剤組成物
WO2000067726A1 (fr) * 1999-05-11 2000-11-16 Charles Walton Champ Procedes et formulations hote-invites pour l'administration de composes bioactifs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61286314A (ja) * 1985-06-11 1986-12-16 Shiseido Co Ltd 口腔用組成物
BE906034A (fr) * 1985-12-24 1987-04-16 Seuref Ag Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
WO1998056336A1 (fr) * 1997-06-12 1998-12-17 C.S. Bioscience Inc. Formulation dentaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1379223A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1607097A2 (fr) * 2003-08-21 2005-12-21 Neutrogena Corporation Compositions stabilisées renfermant des agents qui sont labiles en présence d'oxygène
EP1607097A3 (fr) * 2003-08-21 2006-01-18 Neutrogena Corporation Compositions stabilisées renfermant des agents qui sont labiles en présence d'oxygène
WO2006109344A2 (fr) * 2005-04-13 2006-10-19 Gasparini, Gianluigi Composition pour le traitement de pathologie parodontale
WO2006109344A3 (fr) * 2005-04-13 2007-05-03 Gasparini Gianluigi Composition pour le traitement de pathologie parodontale
WO2007061912A3 (fr) * 2005-11-23 2008-01-31 Coca Cola Co Composition d'edulcorant tres puissant avec un agent anti-inflammatoire et compositions sucrees avec celle-ci
US8435588B2 (en) 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
US8173711B2 (en) 2007-01-31 2012-05-08 Kaneka Corporation Agent for relief or prevention of xerostomia
FR3012294A1 (fr) * 2013-10-25 2015-05-01 Ferco Dev Agents edulcorants a base de stevia.
EP2881105A1 (fr) * 2013-12-05 2015-06-10 PM-International AG Kit de produits de soin dentaire

Also Published As

Publication number Publication date
EP1379223A1 (fr) 2004-01-14
CA2441940A1 (fr) 2002-10-03
JP2004532831A (ja) 2004-10-28
EP1379223A4 (fr) 2005-09-07

Similar Documents

Publication Publication Date Title
US6503483B2 (en) Dental formulation
US6207137B1 (en) Dental formulation
US5925335A (en) Dental formulation
AU2006320846B2 (en) Vehicles for oral care with Magnolia Bark Extract
US20090269288A1 (en) Black pearl toothpaste
CN110812316B (zh) 一种含有多种中药组合物的牙膏和制备方法及其应用
US20070098650A1 (en) Dental formulation
EP1379223A1 (fr) Preparation dentaire
EP1332751A1 (fr) Utilisation d'huile d'olive dans l'elaboration d'un produit d'hygiene orale destine a eliminer ou a reduire la plaque bacterienne et/ou les bacteries presentes dans la cavite buccale
CN102858308A (zh) 一种健齿牙膏组合物
US4853213A (en) Use of periwinkle in oral hygiene
US11723847B2 (en) Dual component oral composition for enhancing remineralization of teeth
RU2334522C1 (ru) Лечебно-профилактический эликсир для ухода за полостью рта
KR980008209A (ko) 치약 조성물
CN108125815A (zh) 一种口腔抗幽门螺旋杆菌和防龋齿健胃功能的牙膏及其制备方法
FR2822700A1 (fr) Nouveau produit d'hygiene dentaire sous forme de nutricament unidose gelifiant d'action prolongee et compositions nouvelles adaptees en comprime ou gel semisolide
KR0179523B1 (ko) 치은염 치료용 유향과 창출 추출물 함유 치약조성물
RU2505283C1 (ru) Композиция зубной пасты
Kaur et al. The immediate Term effect of chewing commercially available Meswak (Salvadora persica) on levels of Calcium, Chloride, Phosphate and Thiocyanate in whole saliva
RU2160585C1 (ru) Состав для профилактики заболеваний полости рта
RU2068688C1 (ru) Лечебно-профилактическая зубная паста "фортуна"
US20240148619A1 (en) Dual component oral composition for enhancing remineralization of teeth
WO2006110183A2 (fr) Preparation dentifrice
RU2123324C1 (ru) Состав для профилактики кариеса зубов и заболеваний пародонта "микродент"
Teli et al. Review Of Cetylpyridium Chloride Combination With Azadirachta Indica Extract Antibacterial And Antimicrobial Effervescent Mouthwash

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2441940

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002574949

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001274034

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001274034

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642